FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379979757> ?p ?o ?g. }

• W4379979757 endingPage "693" @default.
• W4379979757 startingPage "692" @default.
• W4379979757 abstract "Introduction: Primary central nervous system lymphoma (PCNSL) is a rare disease with an incidence of 0.4/per 100,000 person-years. As there is a limited number of prospective randomized trials in PCNSL, large retrospective studies on this rare disease may yield information that might prove useful for the future design of randomized clinical trials. Methods: We retrospectively analyzed the data of 222 newly diagnosed PCNSL patients treated in 5 referral centers in Israel between 2001 and 2020. During this period, combination therapy became the treatment of choice, rituximab has been added to the induction therapy, and consolidation with irradiation was largely laid off and was mostly replaced by high-dose chemotherapy with or without autologous stem cell transplantation. Results: Patients older than 60 comprised 67.5% of the study population. First-line treatment included high-dose methotrexate (HD-MTX) in 94% of patients with a median MTX dose of 3.5 gr/m2 (range 1.14–6 gr/m2) and a median cycle number of 5 (range 1–16). Rituximab was given to 136 patients (61%) and consolidation treatment to 124 patients (58%). Patients treated after 2012 received significantly more treatment with HD-MTX and rituximab, more consolidation treatments, and autologous stem cell transplantation. The overall response rate was 85% and the complete response (CR)/unconfirmed CR rate was 62.1%. After a median follow-up of 24 months, the median PFS and OS were 21.9 and 43.5 months respectively with a significant improvement since 2012 (PFS:12.5 vs. 34.2 p = 0.006 and OS: 19.9 vs. 77.3 p = 0.0003). A multivariate analysis found that the most important factors related to OS were obtaining a CR followed by rituximab treatment and ECOG performance status. Conclusions: The observed improvement in outcomes may be due to multiple components such as an intention to treat all patients regardless of age with HD-MTX- based combination chemotherapy, treatment in dedicated centers, and more aggressive consolidation with the introduction of HDC-ASCT. The research was funded by: No funding Keywords: diagnostic and prognostic biomarkers, combination therapies, aggressive B-cell non-Hodgkin lymphoma No conflicts of interests pertinent to the abstract." @default.
• W4379979757 created "2023-06-10" @default.
• W4379979757 creator A5019114648 @default.
• W4379979757 creator A5020728015 @default.
• W4379979757 creator A5029468839 @default.
• W4379979757 creator A5035133990 @default.
• W4379979757 creator A5037546722 @default.
• W4379979757 creator A5038901187 @default.
• W4379979757 creator A5059360959 @default.
• W4379979757 creator A5064408831 @default.
• W4379979757 creator A5070086014 @default.
• W4379979757 creator A5070181461 @default.
• W4379979757 creator A5081490717 @default.
• W4379979757 date "2023-06-01" @default.
• W4379979757 modified "2023-10-12" @default.
• W4379979757 title "A RETROSPECTIVE STUDY OF 222 PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA—OUTCOMES INDICATIVE FOR IMPROVED SURVIVAL OVERTIME" @default.
• W4379979757 doi "https://doi.org/10.1002/hon.3165_545" @default.
• W4379979757 hasPublicationYear "2023" @default.
• W4379979757 type Work @default.
• W4379979757 citedByCount "0" @default.
• W4379979757 crossrefType "journal-article" @default.
• W4379979757 hasAuthorship W4379979757A5019114648 @default.
• W4379979757 hasAuthorship W4379979757A5020728015 @default.
• W4379979757 hasAuthorship W4379979757A5029468839 @default.
• W4379979757 hasAuthorship W4379979757A5035133990 @default.
• W4379979757 hasAuthorship W4379979757A5037546722 @default.
• W4379979757 hasAuthorship W4379979757A5038901187 @default.
• W4379979757 hasAuthorship W4379979757A5059360959 @default.
• W4379979757 hasAuthorship W4379979757A5064408831 @default.
• W4379979757 hasAuthorship W4379979757A5070086014 @default.
• W4379979757 hasAuthorship W4379979757A5070181461 @default.
• W4379979757 hasAuthorship W4379979757A5081490717 @default.
• W4379979757 hasBestOaLocation W43799797571 @default.
• W4379979757 hasConcept C126322002 @default.
• W4379979757 hasConcept C141071460 @default.
• W4379979757 hasConcept C167135981 @default.
• W4379979757 hasConcept C2776694085 @default.
• W4379979757 hasConcept C2779050716 @default.
• W4379979757 hasConcept C2779338263 @default.
• W4379979757 hasConcept C2780653079 @default.
• W4379979757 hasConcept C2781173314 @default.
• W4379979757 hasConcept C2908647359 @default.
• W4379979757 hasConcept C2911091166 @default.
• W4379979757 hasConcept C71924100 @default.
• W4379979757 hasConcept C88879693 @default.
• W4379979757 hasConcept C99454951 @default.
• W4379979757 hasConceptScore W4379979757C126322002 @default.
• W4379979757 hasConceptScore W4379979757C141071460 @default.
• W4379979757 hasConceptScore W4379979757C167135981 @default.
• W4379979757 hasConceptScore W4379979757C2776694085 @default.
• W4379979757 hasConceptScore W4379979757C2779050716 @default.
• W4379979757 hasConceptScore W4379979757C2779338263 @default.
• W4379979757 hasConceptScore W4379979757C2780653079 @default.
• W4379979757 hasConceptScore W4379979757C2781173314 @default.
• W4379979757 hasConceptScore W4379979757C2908647359 @default.
• W4379979757 hasConceptScore W4379979757C2911091166 @default.
• W4379979757 hasConceptScore W4379979757C71924100 @default.
• W4379979757 hasConceptScore W4379979757C88879693 @default.
• W4379979757 hasConceptScore W4379979757C99454951 @default.
• W4379979757 hasIssue "S2" @default.
• W4379979757 hasLocation W43799797571 @default.
• W4379979757 hasOpenAccess W4379979757 @default.
• W4379979757 hasPrimaryLocation W43799797571 @default.
• W4379979757 hasRelatedWork W2069377710 @default.
• W4379979757 hasRelatedWork W2106168795 @default.
• W4379979757 hasRelatedWork W2411583971 @default.
• W4379979757 hasRelatedWork W2421063030 @default.
• W4379979757 hasRelatedWork W2591056630 @default.
• W4379979757 hasRelatedWork W2621307899 @default.
• W4379979757 hasRelatedWork W2781286807 @default.
• W4379979757 hasRelatedWork W31297289 @default.
• W4379979757 hasRelatedWork W4319262799 @default.
• W4379979757 hasRelatedWork W4380088657 @default.
• W4379979757 hasVolume "41" @default.
• W4379979757 isParatext "false" @default.
• W4379979757 isRetracted "false" @default.
• W4379979757 workType "article" @default.